These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15818309)

  • 41. Enfuvirtide, a new drug for HIV infection.
    Fletcher CV
    Lancet; 2003 May; 361(9369):1577-8. PubMed ID: 12747873
    [No Abstract]   [Full Text] [Related]  

  • 42. [Spanish recommendations for proper use of enfuvirtide].
    Ribera E; Moreno S; Viciana P; Echevarría S; Flores J; Francés A; Gómez-Sirvent JL; González J; Hernández-Quero J; Lozano F; Mallolas J; Muñoz A; Ocampo A; Portilla J; Pulido F; Rivero A; Santos J; Soriano V; Antela A; Arazo P; Arribas JR; Cervantes M; Domingo P
    Enferm Infecc Microbiol Clin; 2007 Feb; 25(2):131-42. PubMed ID: 17288910
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fuzeon treatment forum, January 2004.
    Burgess GE
    Surviv News (Atlanta Ga); 2004; 15(1):10. PubMed ID: 15032144
    [No Abstract]   [Full Text] [Related]  

  • 44. Enfuvirtide nursing guidelines: a report from the Association of Nurses in AIDS Care Expert Panel on Enfuvirtide.
    Foy K; Bradley-Springer L; Kempner T; Stevens L; Gahagan L
    J Assoc Nurses AIDS Care; 2005; 16(2):2-12. PubMed ID: 16438121
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successful desensitization of enfuvirtide after a first attempt failure.
    Machado ES; Passoni LF; Sidi LC; Andrade HB; De Menezes JA
    AIDS; 2006 Oct; 20(16):2130-1. PubMed ID: 17053365
    [No Abstract]   [Full Text] [Related]  

  • 46. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
    Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
    Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interaction between enfuvirtide, an injectable fusion inhibitor, and niacin in an HIV-infected patient.
    Oates E; Dzintars K
    Ann Pharmacother; 2010 Dec; 44(12):2014-7. PubMed ID: 21045170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of HIV fusion inhibitors.
    Schneider SE; Bray BL; Mader CJ; Friedrich PE; Anderson MW; Taylor TS; Boshernitzan N; Niemi TE; Fulcher BC; Whight SR; White JM; Greene RJ; Stoltenberg LE; Lichty M
    J Pept Sci; 2005 Nov; 11(11):744-53. PubMed ID: 16130177
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children.
    Church JA; Hughes M; Chen J; Palumbo P; Mofenson LM; Delora P; Smith E; Wiznia A; Hawkins E; Sista P; Cunningham CK;
    Pediatr Infect Dis J; 2004 Aug; 23(8):713-8. PubMed ID: 15295220
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.
    DeJesus E; Gottlieb MS; Gathe JC; Greenberg ML; Guittari CJ; Zolopa AR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4315-9. PubMed ID: 18809940
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enfuvirtide: a new class of antiretroviral therapy for HIV infection.
    Leao JC; Frezzini C; Porter S
    Oral Dis; 2004 Nov; 10(6):327-9. PubMed ID: 15533206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?
    Morse C; Maldarelli F
    J Infect Dis; 2007 Feb; 195(3):318-21. PubMed ID: 17205468
    [No Abstract]   [Full Text] [Related]  

  • 53. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.
    Marcial M; Lu J; Deeks SG; Ziermann R; Kuritzkes DR
    J Clin Microbiol; 2006 Sep; 44(9):3384-7. PubMed ID: 16954280
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough.
    Meyohas MC; Lacombe K; Carbonne B; Morand-Joubert L; Girard PM
    AIDS; 2004 Sep; 18(14):1966-8. PubMed ID: 15353987
    [No Abstract]   [Full Text] [Related]  

  • 55. [Enfuvirtide].
    Gerstoft J
    Ugeskr Laeger; 2004 Nov; 166(48):4355-7. PubMed ID: 15587625
    [No Abstract]   [Full Text] [Related]  

  • 56. [Enfuvirtide: first drug of a new family of antiretroviral agents].
    Espona M; Ferrández O; Grau S; Carmona A
    Farm Hosp; 2005; 29(6):375-83. PubMed ID: 16433570
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Localized amyloidosis at the site of enfuvirtide injection.
    Morilla ME; Kocher J; Harmaty M
    Ann Intern Med; 2009 Oct; 151(7):515-6. PubMed ID: 19805777
    [No Abstract]   [Full Text] [Related]  

  • 58. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.
    Streinu-Cercel A; de Gorgolas M; Müller M; Portilla J; Rugina S; Böcher W; Staszewski S; Pulik P; Rowell L; Salgo M; Stoll M
    HIV Clin Trials; 2008; 9(6):375-86. PubMed ID: 19203903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Enfuvirtide. Two injections per day for HIV].
    Taéron C
    Rev Infirm; 2004 Oct; (104):35-6. PubMed ID: 15581312
    [No Abstract]   [Full Text] [Related]  

  • 60. Virologic and immunologic impact and durability of enfuvirtide-based antiretroviral therapy in HIV-infected treatment-experienced patients in a clinical setting.
    Loutfy MR; Antoniou T; Shen S; Diong C; Vlaicu M; Halpenny R; Kovacs C; Fletcher D; Raboud JM
    HIV Clin Trials; 2007; 8(1):36-44. PubMed ID: 17434847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.